<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2026-02-21</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2026-02-21</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>43</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
èšç„¦è‚¿ç˜¤å…ç–«æ²»ç–—æ–°ç­–ç•¥ï¼Œå¦‚åŒé¶å‘STING/PI3KÎ³è”åˆç–—æ³•åœ¨èƒ°è…ºç™Œä¸­çš„åº”ç”¨ï¼Œä»¥åŠmiRNAè°ƒæ§è‚¿ç˜¤å¾®ç¯å¢ƒå¯¹è‚ºç™Œå…ç–«æ²»ç–—çš„å½±å“ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
*   <strong>è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒé‡å¡‘ä¸è°ƒæ§</strong>ï¼šç ”ç©¶miR-29a/b1åœ¨è‚ºç™Œä¸­çš„å¤±è°ƒå¦‚ä½•é‡å¡‘è‚¿ç˜¤å¾®ç¯å¢ƒå¹¶å¯¼è‡´å…ç–«æŠ‘åˆ¶ï¼›æ¢ç´¢STING/PI3KÎ³åŒé¶å‘ç­–ç•¥åœ¨å…‹æœèƒ°è…ºç™Œå…ç–«æŠµæŠ—ä¸­çš„ä½œç”¨ã€‚<br />
*   <strong>ç»†èƒå¼‚è´¨æ€§ä¸åŠŸèƒ½æœºåˆ¶è§£æ</strong>ï¼šåˆ©ç”¨å•ç»†èƒè½¬å½•ç»„å­¦æ­ç¤ºè‚ç»†èƒç™Œä¸­ç‰¹å¼‚æ€§Tç»†èƒçš„å¼‚è´¨æ€§ï¼›è§£æSHMT2åœ¨èƒ°è…ºç™Œè¿›å±•ä¸­çš„ä½œç”¨ã€‚<br />
*   <strong>ä¿¡å·é€šè·¯ä¸ç–¾ç—…å…³è”</strong>ï¼šç ”ç©¶CD36/FABP5/PPARÎ´ä¿¡å·è½´åœ¨æ–°ç”ŸæœŸå¿ƒè‚Œç»†èƒå¢æ®–ä¸­çš„ä½œç”¨ï¼›æ¢ç©¶TAK1ä¿¡å·é€šè·¯å¯¹å¿ƒè‚Œæˆçº¤ç»´ç»†èƒè½¬å½•ç»„çš„å½±å“ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
*   <strong>å¤šç»„å­¦æ•´åˆåˆ†æ</strong>ï¼šç»“åˆå•ç»†èƒRNAæµ‹åºï¼ˆscRNA-seqï¼‰ã€å…¨åŸºå› ç»„ç»“åˆ/å ç”¨è°±åˆ†æï¼ˆATAC-seqï¼‰ç­‰æŠ€æœ¯ï¼Œæ·±å…¥è§£æå¤æ‚ç–¾ç—…ï¼ˆå¦‚é˜¿å°”èŒ¨æµ·é»˜ç—…ï¼‰çš„ç»†èƒå’Œåˆ†å­æœºåˆ¶ã€‚<br />
*   <strong>ç©ºé—´è½¬å½•ç»„å­¦</strong>ï¼šåº”ç”¨äºå¿ƒè‚Œç»†èƒç ”ç©¶ï¼Œæä¾›ç»†èƒå¾®ç¯å¢ƒä¿¡æ¯ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ–°å‹å•ç»†èƒå¤šç»„å­¦æŠ€æœ¯scHiCARé¦–æ¬¡å®ç°è½¬å½•ç»„ã€è¡¨è§‚åŸºå› ç»„å’Œ3DåŸºå› ç»„çš„è”åˆåˆ†æï¼›äººä½“é¦–æ¬¡å‘ç°è°ƒæ§ç‚ç—‡çš„å¤©ç„¶â€œå…³é—­å¼€å…³â€ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- å•ç»†èƒå¤šç»„å­¦æŠ€æœ¯å¼€å‘ä¸åº”ç”¨<br />
- ç‚ç—‡è°ƒæ§æœºåˆ¶ç ”ç©¶<br />
- DNAæµ‹åºä¸ç±»è„‘è®¡ç®—æŠ€æœ¯çªç ´<br />
- åŒ–å¦†å“å®‰å…¨æ€§æ£€æµ‹</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- scHiCARæ•´åˆRNA-seqã€ATAC-seqåŠHi-CæŠ€æœ¯ï¼Œå®ç°å•ç»†èƒå±‚é¢å¢å¼ºå­-å¯åŠ¨å­äº’ä½œåˆ†æã€‚<br />
- å‘ç°è„‚è‚ªæ¥æºçš„ç¯æ°§äºŒåç¢³ä¸‰çƒ¯é…¸ç±»åˆ†å­ï¼ˆepoxy-oxylipinsï¼‰å¯æŠ‘åˆ¶å…ç–«ç»†èƒæ´»åŒ–ï¼Œè°ƒæ§ç‚ç—‡ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (39æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE285606 miR-29a/b1ç°‡çš„ç¼ºå¤±é‡ç¼–ç¨‹è‚¿ç˜¤å¾®ç¯å¢ƒå¹¶å¯¼è‡´è‚ºç™Œå…ç–«æŠ‘åˆ¶</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€tumor microenvironmentã€regex:immuno(logy|therapy|suppression)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jessica Konen ; Yanhua Tian ; Yuanxin XiSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusImmune checkpoint inhibitors (ICI), like those that block PD-1/PD-L1, have revolutionized oncological therapy for patients with non-small cell lung cancer (NSCLC). However, most patients demonstrate no clinical benefit or acquire resistance, even in PD-L1+ populations, highlighting the critical need to dissect tumor survival dependencies to overcome resistance. Using our unique Kras/p53-driven lung cancer models which demonstrate acquired or intrinsic resistance to ICI, we performed single cell RNA-sequencing and focused on predicted upstream regulators of differentially expressed genes (DEGs) in the malignant cell cluster of resistant tumors. We found that the micro-RNA, miR-29, was downregulated in tumors with anti-PD-1 resistance, leading to significant upregulation of a multitude of miR-29 targets. Interestingly, we found that the immunosuppressive molecule Enpp2/ATX was one of these genes modulated due to miR-29 loss, and re-expression of miR-29 in anti-PD-1 resistant models diminished ATX tumor expression, diminished the fibrotic microenvironment, and increased CD8 infiltration. Additionally, analysis of lung adenocarcinoma patients revealed miR-29-high patients had increased CD8A expression and enrichment in immunoregulatory pathways. Together, these data provide evidence that the miR-29 family broadly regulates the tumor microenvironment, including anti-tumor immune-related pathways in lung cancer, through control of ATX among many other target genes, with implications in ICI response.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285606" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE275785 åŒé‡é¶å‘ STING å’Œ PI3KÎ³ å¯æ¶ˆé™¤è°ƒèŠ‚æ€§ B ç»†èƒä»¥å…‹æœèƒ°è…ºç™Œå…ç–«ç–—æ³•çš„ STING è€è¯æ€§ [scRNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€regex:immuno(logy|therapy|suppression)ã€resistanceã€scRNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Chengyi Li ; Duxin SunSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe immune suppression in tumors and lymph nodes of pancreatic ductal adenocarcinoma (PDAC), regulated by suppressive myeloid cells and regulatory B (Breg) cells, hinders the effectiveness of immunotherapy. Although STING agonists activate myeloid cells to overcome immune suppression, it expands Breg cells, conferring STING resistance in PDAC. We discovered that blocking PI3KÎ³ during STING activation abolished IRF3 phosphorylation to eliminate Breg cells, while PI3KÎ³ inhibition sustained STING-induced IRF3 phosphorylation to preserve STING function in myeloid cells. Therefore, we developed a dual functional compound SH-273 and its albumin nanoformulation Nano-273, which stimulates STING to activate myeloid cells and inhibits PI3KÎ³ to eliminates Breg cells overcoming STING resistance. Nano-273 achieved systemic antitumor immunity through intravenous administration, which decreases Breg cells and remodels microenvironment in tumors and lymph nodes. Nano-273, combined with anti-PD-1, extended median survival to 200 days in transgenic KPC PDAC mice (KrasG12D-P53R172H-Cre), offering potential for PDAC treatment.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275785" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE275780 åŒé‡é¶å‘ STING å’Œ PI3KÎ³ å¯æ¶ˆé™¤è°ƒèŠ‚æ€§ B ç»†èƒä»¥å…‹æœèƒ°è…ºç™Œå…ç–«ç–—æ³•çš„ STING è€è¯æ€§ [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€regex:immuno(logy|therapy|suppression)ã€resistanceã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Chengyi Li ; Duxin SunSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe immune suppression in tumors and lymph nodes of pancreatic ductal adenocarcinoma (PDAC), regulated by suppressive myeloid cells and regulatory B (Breg) cells, hinders the effectiveness of immunotherapy. Although STING agonists activate myeloid cells to overcome immune suppression, it expands Breg cells, conferring STING resistance in PDAC. We discovered that blocking PI3KÎ³ during STING activation abolished IRF3 phosphorylation to eliminate Breg cells, while PI3KÎ³ inhibition sustained STING-induced IRF3 phosphorylation to preserve STING function in myeloid cells. Therefore, we developed a dual functional compound SH-273 and its albumin nanoformulation Nano-273, which stimulates STING to activate myeloid cells and inhibits PI3KÎ³ to eliminates Breg cells overcoming STING resistance. Nano-273 achieved systemic antitumor immunity through intravenous administration, which decreases Breg cells and remodels microenvironment in tumors and lymph nodes. Nano-273, combined with anti-PD-1, extended median survival to 200 days in transgenic KPC PDAC mice (KrasG12D-P53R172H-Cre), offering potential for PDAC treatment.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275780" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE319709 å•ç»†èƒè½¬å½•ç»„å­¦æ­ç¤ºè‚ç»†èƒç™Œä¸­ç—…å› ç‰¹å¼‚æ€§Tç»†èƒå¼‚è´¨æ€§å¹¶æç¤ºå…¶è°ƒæ§æœºåˆ¶</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€single-cellã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Fengna YanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensHepatocellular carcinoma (HCC) exhibits remarkable etiological heterogeneity, with hepatitis B virus (HBV) infection and metabolic dysfunction-associated steatohepatitis (MASH) emerging as two leading causes. The tumor microenvironment (TME), particularly T cell subsets, plays a pivotal role in tumor progression and immunotherapy response. However, the etiology-specific T cell landscapes in HBV-HCC and MASH-HCC remain poorly characterized.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319709" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE310857 ç”¨ SHMT2 æ•²ä½æ…¢ç—…æ¯’ï¼ˆäººï¼‰è½¬æŸ“çš„èƒ°è…ºç™Œç»†èƒçš„è½¬å½•ç»„æµ‹åºã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€sequencingã€transcriptome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe role of SHMT2 in driving pancreatic cancer progression remains incompletely understood. Our previous findings demonstrated that SHMT2 enhances glycolytic metabolism and promotes proliferative and invasive capacities in pancreatic cancer cells. To delineate the precise molecular mechanism underlying these observations, we performed transcriptomic sequencing.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310857" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE290093 CD36/FABP5/PPARÎ´ä¿¡å·è½´çš„ç©ºé—´è½¬å½•ç»„å­¦å®šä¹‰äº†æ–°ç”Ÿå„¿æœŸè‡ªå‘å¢æ®–çš„å¿ƒè‚Œç»†èƒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šspatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Abou Bakr M Salama ; Tamer M MohamedSeries Type : OtherOrganism : Mus musculusSpontaneously cycling cardiomyocytes (CMs) represent a rare and unique population in the neonatal heart with the potential to drive cardiac regeneration in adulthood. While previous studies have observed their existence, the mechanisms regulating their cell cycle activity remain poorly understood. Here, we aim to identify the signaling axis that defines the spontaneously proliferating CMs in the neonatal stage.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290093" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE225630 è½¬ç§»å‰è‚¿ç˜¤å¼•æµæ·‹å·´ç»“çš„è½¬å½•ç»„ï¼Œä¼´æˆ–ä¸ä¼´ TDLN æ”¯é…ä¼¤å®³æ€§ç¥ç»çš„å»ç¥ç»æ”¯é…</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€lymphã€regex:lymph(o|atic)?<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Yu Zhang ; Yibo Guo ; Tong JiSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusWe compared the mice tumor-draining lymph nodes(TDLNs) with or without orthotopic tongue xenografts, and with or without denervation of TDLN-innervating nociceptive nerves<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225630" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE293149 è¡°è€æ§åˆ¶ä¸­ç²¾å­å‘ç”Ÿç‰¹å¼‚æ€§ Argonaute è›‹ç™½å’Œèƒ°å²›ç´ /IGF-1 ä¿¡å·ä¼ å¯¼çš„ç›¸äº’è°ƒæ§ [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šagingã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Thomas Liontis ; Valentina T Pannarale ; Andres R Mansisidor ; Sasiru K Pathiranage ; Jeeya Y Patel ; Alla GrishokSeries Type : Expression profiling by high throughput sequencingOrganism : Caenorhabditis elegansThe potential role of small interfering RNAs (siRNAs) produced from double-stranded RNA in aging has not been fully addressed.The networks of genes regulated by siRNAs and their partner Argonaute proteins are best understood in C. elegans, a pioneeringmodel of aging and small RNA studies. Here, we describe synergistic lifespan extension of insulin/IGF-1 signaling (IIS) mutant age-1(hx546) by rde-4 or alg-3; alg-4 deï¬ciencies. By analyzing gene expression and siRNA populations in these IIS and RNAi mutants,we show here that redundant spermatogenesis-speciï¬c Argonautes ALG-3 and ALG-4 are capable of regulating IIS, potentially through direct control of the Major Sperm Protein (MSP) genes in the germline. MSPs and MSP domains of some mammalian proteins are secreted and directly inhibit the Eph receptor (EphR). In turn, EphR interacts with and destabilizes PTEN, a major negative regulator of IIS. We show that enhanced MSP expression correlates with EphR mislocalization and elevated PTEN levels in oocytes of alg-3/4(-) worms. At the same time, ALG-3/4 expression is regulated by IIS. Thus, we propose mutual regulation of IIS and ALG-3/4 through secreted ligands.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293149" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE316734 å­å®«å†…è†œç™Œå’Œåµå·¢ç™Œç»†èƒç³»å¯¹DHX9æŠ‘åˆ¶å‰‚çš„æ•æ„Ÿæ€§å’Œè€è¯æœºåˆ¶çš„è¡¨å¾</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Huang Tzu-TingSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTo investigate the DHX9i response across endometrial and ovarian cancer cell lines with diverse backgrounds, total RNA was isolated from three biological replicates of cells treated with or without ATX968 (a DHX9 inhibitor). The RNA samples were then subjected to paired-end RNA sequencing on the NovaSeq X Plus (Illumina) platform.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316734" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE304899 B ç»†èƒå†…åœ¨ I å‹å¹²æ‰°ç´ ä¿¡å·ä¼ å¯¼å¯¼è‡´ç–«è‹—ç¼ºé™· [VDJ]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼švaccineã€B cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xavier LaulhÃ© ; Yasmine Adda-Bouchard ; Guillaume Lopez ; Gabriel Chamberlain ; Anolie Dubreuil ; Tania Charpentier ; Alain LamarreSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusAffinity maturation and vaccine efficacy are compromised during chronic viral infections, yet the underlying mechanisms remain unclear. Using the LCMV Cl13 model, we show that IFN-I signaling in B cells plays a central role. IFN-I promotes early B cell activation but reduces clonal diversity and delays IgG1âº B cell entry into germinal centers, impairing high-affinity clone selection. Deletion of IFNAR1 in B cells partially restores NP-specific IGHV1-72 usage and GC access but fails to fully rescue affinity maturation, suggesting a contribution of extrinsic factors. Somatic hypermutation remains elevated in both genotypes, though slightly reduced in IFNAR1â»/â» B cells. BASELINe analysis indicates weaker selection pressure in CDRs, potentially reflecting impaired affinity-based selection. This defect correlates with a reduced TFR/TFH ratio. Our results show that intrinsic and extrinsic IFN-I-dependent mechanisms synergize to disrupt B cell fate. These findings establish IFN-I as a key regulator of humoral immunity and highlight mechanisms underlying poor vaccine response.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304899" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 29 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (4æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>scHiCARâ€”â€”è½¬å½•ç»„ã€è¡¨è§‚åŸºå› ç»„å’Œ3DåŸºå› ç»„çš„ä¸‰æ¨¡æ€å•ç»†èƒåˆ†æ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsingle-cellã€genomeã€transcriptomeã€epigenome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šscHiCAR integrates RNA sequencing, chromatin accessibility, and 3D genome mapping in single cells, enabling high-resolution analysis of enhancer promoter interactions across complex tissues...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/schicar-trimodal-single-cell-profiling-of-transcriptome-epigenome-and-3d-genome/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>ç§‘å­¦å®¶å‘ç°äººä½“éšè—çš„ç‚ç—‡â€œå…³é—­å¼€å…³â€ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šinflammation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šA new human study has uncovered how the body naturally turns off inflammation. Researchers found that fat-derived molecules called epoxy-oxylipins rein in immune cells that can otherwise drive chronic disease. Using a drug to boost these molecules reduced pain faster and lowered harmful inflammatory cells. The discovery could pave the way for safer treatments for arthritis, heart disease, and other inflammation-related conditions.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260219040816.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>åŸå­çº§é—¨æ§æŠ€æœ¯æœ‰æœ›å½»åº•æ”¹å˜DNAæµ‹åºå’Œç¥ç»å½¢æ€è®¡ç®—ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencing<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šScientists have taken a major step toward mimicking natureâ€™s tiniest gateways by creating ultra-small pores that rival the dimensions of biological ion channelsâ€”just a few atoms wide. The breakthrough opens new possibilities for single-molecule sensing, neuromorphic computing, and studying how matter behaves in spaces barely larger than atoms.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260219040759.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>ç§‘å­¦å®¶åœ¨æµè¡Œçš„å‡å‘ç‰‡ä¸­å‘ç°è‡´ç™ŒåŒ–å­¦ç‰©è´¨</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šA sweeping new study has uncovered a troubling mix of hazardous chemicals in popular hair extensions, including products made from human hair. Researchers detected dozens of substances linked to cancer, hormone disruption, reproductive harm, and immune system effects in nearly every sample tested. Some products contained flame retardants, organotins, and chemicals associated with increased breast cancer risk, and several exceeded European safety thresholds.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260219232620.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA-seq</td>
<td>9</td>
</tr>
<tr>
<td>transcriptome</td>
<td>8</td>
</tr>
<tr>
<td>cancer</td>
<td>8</td>
</tr>
<tr>
<td>sequencing</td>
<td>5</td>
</tr>
<tr>
<td>scRNA</td>
<td>4</td>
</tr>
<tr>
<td>single-cell</td>
<td>3</td>
</tr>
<tr>
<td>resistance</td>
<td>3</td>
</tr>
<tr>
<td>regex:immuno(logy</td>
<td>therapy</td>
</tr>
<tr>
<td>aging</td>
<td>2</td>
</tr>
<tr>
<td>inflammation</td>
<td>2</td>
</tr>
<tr>
<td>T cell</td>
<td>2</td>
</tr>
<tr>
<td>vaccine</td>
<td>2</td>
</tr>
<tr>
<td>B cell</td>
<td>2</td>
</tr>
<tr>
<td>regex:intestin(e</td>
<td>al)</td>
</tr>
<tr>
<td>tumor</td>
<td>2</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>2</td>
</tr>
<tr>
<td>genome</td>
<td>1</td>
</tr>
<tr>
<td>epigenome</td>
<td>1</td>
</tr>
<tr>
<td>metabolic</td>
<td>1</td>
</tr>
<tr>
<td>tumor microenvironment</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (29æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304898" target="_blank" rel="noopener noreferrer">GSE304898 B ç»†èƒå†…åœ¨ I å‹å¹²æ‰°ç´ ä¿¡å·ä¼ å¯¼å¯¼è‡´ç–«è‹—ç¼ºé™· [GEX]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319605" target="_blank" rel="noopener noreferrer">GSE319605 äººç±»å¿ƒè„ Treg ç»†èƒçš„å•ç»†èƒ RNA æµ‹åº (SORT-seq) (QMU-SF-s001â€“QMU-SF-s012)</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319453" target="_blank" rel="noopener noreferrer">GSE319453 ç³–å°¿ç—…å’Œè„“æ¯’ç—‡å°é¼ è‚ é“è½¬å½•ç»„åˆ†æ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319365" target="_blank" rel="noopener noreferrer">GSE319365 è‚ºæ³¡å·¨å™¬ç»†èƒçš„è®­ç»ƒå…ç–«é€šè¿‡å¢å¼º KLF4-MERTK ä»‹å¯¼çš„èƒåä½œç”¨ä¿ƒè¿›æŸä¼¤æ¶ˆé€€ [ATAC-seq 72h post-LPS]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300520" target="_blank" rel="noopener noreferrer">GSE300520 é¢éƒ¨æµ¸æ¶¦æ€§è„‚è‚ªç˜¤æˆ–å¯¹ç…§ç»„åˆ†ç¦»çš„è„‚è‚ªç»„ç»‡è½¬å½•ç»„æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294332" target="_blank" rel="noopener noreferrer">GSE294332ï¼šå¯¹é˜¿å°”èŒ¨æµ·é»˜ç—…å°é¼ æ¨¡å‹è¿›è¡Œå¤šç»„å­¦å•æ ¸åˆ†æè¡¨æ˜ï¼ŒACSS2èµ‹äºˆç¥ç»å…ƒæŠµæŠ—tauè›‹ç™½ç—…å˜çš„èƒ½åŠ›ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290127" target="_blank" rel="noopener noreferrer">GSE290127 TAK1ä¿¡å·é€šè·¯å¯¹å¿ƒè„æˆçº¤ç»´ç»†èƒè½¬å½•ç»„çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304872" target="_blank" rel="noopener noreferrer">GSE304872 å‰å…°-å·´é›·ç»¼åˆå¾æ—©æœŸå¤–å‘¨ç¥ç»é¶å‘å’Œç–¼ç—›ä¿ƒè¿›è½¬å½•ç»„ç‰¹å¾ [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304871" target="_blank" rel="noopener noreferrer">GSE304871 å‰å…°-å·´é›·ç»¼åˆå¾æ—©æœŸå¤–å‘¨ç¥ç»é¶å‘å’Œç–¼ç—›ä¿ƒè¿›è½¬å½•ç»„ç‰¹å¾[æ‰¹é‡RNAæµ‹åº]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303753" target="_blank" rel="noopener noreferrer">GSE303753 é€šè¿‡å¢å¼ºä»£è°¢é€šé‡ä¿ƒè¿›ç”Ÿè‚²é…šç”Ÿç‰©åˆæˆå’Œè´¨ä½“çƒå¢æ®–æ¥å¼ºåŒ–å¶ç‰‡åŒ–å­¦ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293150" target="_blank" rel="noopener noreferrer">GSE293150 è¡°è€æ§åˆ¶ä¸­ç²¾å­å‘ç”Ÿç‰¹å¼‚æ€§ Argonaute è›‹ç™½å’Œèƒ°å²›ç´ /IGF-1 ä¿¡å·ä¼ å¯¼çš„ç›¸äº’è°ƒæ§ [smallRNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270345" target="_blank" rel="noopener noreferrer">GSE270345 çŠ¬ä¹³ç®¡ä¹³å¤´çŠ¶ä¹³è…ºè‚¿ç˜¤è½¬å½•ç»„</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316426" target="_blank" rel="noopener noreferrer">GSE316426 MondoAä»‹å¯¼MYCç½‘ç»œä¸èƒ°è…ºå¯¼ç®¡è…ºç™Œæ•´åˆåº”æ¿€ååº”ä¹‹é—´çš„è½¬å½•åè°ƒ[RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307746" target="_blank" rel="noopener noreferrer">GSE307746 æ€¥æ€§å­£èŠ‚æ€§æµæ„Ÿæ„ŸæŸ“æœŸé—´ä¸‹å‘¼å¸é“ä¸­äºº CD8+ T ç»†èƒçš„ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289318" target="_blank" rel="noopener noreferrer">GSE289318 WNTä»‹å¯¼çš„è‚ ä¸Šçš®è½¬åŒ–è¿‡ç¨‹ä¸­åŸºè´¨Pdgfraè¡¨è¾¾ç»†èƒçš„åŠ¨æ€é‡ç¼–ç¨‹ - å›¾3J</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274811" target="_blank" rel="noopener noreferrer">GSE274811 RNAæµ‹åºï¼šè¿‡è¡¨è¾¾é”šå®šMafG-MITF (T-MGM) çš„WM164ç»†èƒ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295103" target="_blank" rel="noopener noreferrer">GSE295103 å°é¼ è‚¾è„å‡ºç”Ÿåå‘è‚²è¿‡ç¨‹ä¸­çš„å•æ ¸ RNA æµ‹åºã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319738" target="_blank" rel="noopener noreferrer">GSE319738 æ¶å”‘çƒ·é…®ä»‹å¯¼çš„ç¿»è¯‘æŠ‘åˆ¶çš„ä¸Šä¸‹æ–‡ç‰¹å¼‚æ€§å—æŠ—ç”Ÿç´ ç»“æ„è°ƒæ§ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319710" target="_blank" rel="noopener noreferrer">GSE319710 å•æ ¸ç»†èƒé€šè¿‡è¡€å°æ¿ç›¸äº’ä½œç”¨å’Œæ°§åŒ–åº”æ¿€ä¿¡å·ä¼ å¯¼è€Œæˆä¸º HIV ç›¸å…³åŠ¨è„‰ç²¥æ ·ç¡¬åŒ–çš„åŸºç¡€ [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319557" target="_blank" rel="noopener noreferrer">GSE319557 çµé•¿ç±»å²›å¶çš®å±‚ç»†èƒå›¾è°±å’Œæ–°å‹ä¿¡å·å¤„ç†ç­–ç•¥ [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319556" target="_blank" rel="noopener noreferrer">GSE319556 å†…çš®ç»†èƒ TLR4 ä¿¡å·ä¼ å¯¼é©±åŠ¨æ–°ç”Ÿå„¿è„‘è†œç‚å°é¼ æ¨¡å‹ä¸­çš„ç»„ç»‡ç‚ç—‡ã€Claudin-5 å†…åŒ–å’Œè¡€ç®¡å±éšœç ´å</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302847" target="_blank" rel="noopener noreferrer">GSE302847 é“æœ¨çš‚è‹·AIIIé€šè¿‡æŠ‘åˆ¶CAR-Trâ€‹â€‹eg IIå¢å¼ºCAR-Tç»†èƒæ•ˆåŠ›å¹¶é¢„é˜²å¤å‘</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290002" target="_blank" rel="noopener noreferrer">GSE290002 CDK8/19æŠ‘åˆ¶å‰‚åœ¨ç»“ç›´è‚ ç™Œä¸­çš„é€‰æ‹©æ€§å’Œæ´»æ€§çš„ç¡®è®¤[ä½“å¤–]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290001" target="_blank" rel="noopener noreferrer">GSE290001 CDK8/19æŠ‘åˆ¶å‰‚åœ¨ç»“ç›´è‚ ç™Œä¸­çš„é€‰æ‹©æ€§å’Œæ´»æ€§çš„ç¡®è®¤[ä½“å†…]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279009" target="_blank" rel="noopener noreferrer">GSE279009 å°é¼ èƒšèƒå¿ƒè„ä¸­PCBP1çš„å¢å¼ºå‹äº¤è”å…ç–«æ²‰æ·€æµ‹åºï¼ˆeCLIP-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279008" target="_blank" rel="noopener noreferrer">GSE279008 èƒšèƒå¿ƒè„è½¬å½•ç»„ï¼Œå¿ƒè‚Œç»†èƒç‰¹å¼‚æ€§ç¼ºä¹ Pcbp1</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279007" target="_blank" rel="noopener noreferrer">GSE279007 æˆå¹´å¿ƒè„ä¸­Aars2ç‰¹å¼‚æ€§å¿ƒè‚Œç»†èƒç¼ºé™·çš„è½¬å½•ç»„</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279006" target="_blank" rel="noopener noreferrer">GSE279006 å¿ƒè‚Œç»†èƒç‰¹å¼‚æ€§Aars2ç¼ºé™·çš„èƒšèƒå¿ƒè„è½¬å½•ç»„</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE256144" target="_blank" rel="noopener noreferrer">GSE256144 RNA-seq åœ¨ DDX24 æ•²ä½å HUVECs ä¸­çš„åº”ç”¨</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-02-20 21:46</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>